Here's how NC Biotech Center invested nearly $2M in state's life science sector
Summary
RESEARCH TRIANGLE PARK – The North Carolina Biotechnology Center awarded 34 grants and loans totaling nearly $2 million to universities, biosciences companies and other entities in the fourth quarter of its last fiscal year. • Wake County received $100,000 to support training for Cellectis employees as the company establishes its first North American manufacturing facility for CAR-T cancer cell therapies in Raleigh. • Duke University Medical Center received $20,000 for preclinical studies to determine whether its nasal vaccine formulation provides lasting immunity against SARS-CoV-2, which localizes in the respiratory tract. • East Carolina University received $20,000 to produce and test several vaccines against SARS-CoV-2 using a patented poxvirus platform to generate enhanced immune responses and increased protection against the virus. • RTI International of Research Triangle Park received $110,000 to develop a liquid formulation of hydroxychloroquine sulfate, a drug currently approved for the treatment of lupus, rheumatoid arthritis and malaria.